Helixgate https://validator.w3.org/feed/docs/rss2.html Home STAT+: The shortage of many medicines in the U.S. remains a ‘systemic’ problem, a new analysis finds Hikma outlines plan to invest $267M in Ohio plants, creating 350 jobs First-in-Human Trial Reports Promising Dual Lassa–Rabies Vaccine Data Incyte to Acquire Vega Therapeutics for Up-to-$2B, Growing Hematology Pipeline with Phase III VWD Candidate Diabetes Association in uproar after members expelled from annual meeting over protest of NIH cuts Update: Parabilis projects possibly record-breaking $637M IPO Merck, Gilead report mixed outcomes in key lung cancer, HIV studies Trump administration warns more than 500 hospitals to provide more price information or face fines Complete Connectome of Fruit Fly Central Nervous System Now Open-Source Crystalys doses first patients in Phase II gout trial  Four years and 219 lost companies later, biotech still has a cash problem STAT+: Pharmalittle: We’re reading about a $10.6 billion GSK deal, an AstraZeneca obesity pill, and more Merck, Gilead serve ‘sweet and sour’ spread after HIV win, cancer stumble STAT+: NIH staffers published a letter of dissent a year ago. They feel it’s been ignored ADA: AstraZeneca hands Structure a win with ‘relatively underwhelming’ GLP-1 pill data STAT+: What’s changed since the last major Ebola outbreak GSK pays $10.6B for cancer biotech Nuvalent in industry’s second-biggest buy of the year ADA: Lilly bests Novo again, takes GLP-1 pill Foundayo to FDA for diabetes approval Opinion: Why STAT is sticking with ‘health care’ as two words Fueled by M&A and partnerships, biotech is poised for continued growth: EY STAT+: GSK to buy Nuvalent, maker of targeted cancer drugs, for $10.6B Alcohol study discarded by Trump officials is published in scientific journal Defective HIV RNA Linked to Persistent Viremia During Long-Term ART Hybrid solid−liquid optics enable scalable, high-resolution light-sheet microscopy across diverse immersion media Health workers at the epicenter of Congo’s Ebola outbreak labor with little pay or rest City banks nearly $100M for next-gen RNAi drugs Regeneron-backed City builds RNAi pipeline with $99.5M series B City Therapeutics builds RNAi pipeline with $99.5M series B Chikungunya Vaccine Development in Africa Accelerated by ACT-CHIK ADA: Novo boasts deep pipeline, ‘breadth of assets’ after analysts award Lilly weight loss gold Roche stakes $700M on Nurix’s protein-degrading drug J&J glows with $1B buyout of Firefly and its degrader platform tech Tango data add to growing momentum for pancreatic cancer drugs Incyte to buy blood disorder drug in possibly $2B deal City aims to lay foundation for RNAi renaissance with nearly $100M series B CiteSentinel Launched to Detect and Prevent AI Hallucinations in Legal Citations CRISPR Shreds Undruggable Cancer Cells with Precision STAT+: UnitedHealthcare’s lactation billing feud, and fake strokes Incyte’s stars align as new CEO strikes $2B Vega takeover for blood disorder asset STAT+: Pharmalittle: We’re reading about Lilly and Pfizer obesity drug data, Roche and J&J deals, and more Boehringer leans on fat mass benefits as obesity bet delivers ‘less competitive’ weight reduction Major readouts from the annual diabetes conference STAT+: Combination of pancreatic cancer drugs from Tango, Revolution leads to high response rate ADA: Lilly sets ‘new record in Weight Loss Olympics’ with next-gen asset IMU Biosciences raises $53m to expand disease platform Innovation alone is no longer enough in biopharma Opinion: American horses are obese, too Busy FDA gives rare disease sector complementary pathways, unanswered questions Design and evolution of the tetracycline repressor into sulfonylurea herbicide-responsive gene switches for field crops